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An accurate prediction of the clinical outcomes of European patients requiring hospitalisation for 
Coronavirus Disease 2019 (COVID‑19) is lacking. The aim of the study is to identify predictors of 
in‑hospital mortality and discharge in a cohort of Lombardy patients with COVID‑19. All consecutive 
hospitalised patients from February 21st to March 30th, 2020, with confirmed COVID‑19 from the 
IRCCS Policlinico San Matteo, Pavia, Lombardy, Italy, were included. In‑hospital mortality and 
discharge were evaluated by competing risk analysis. The Fine and Gray model was fitted in order to 
estimate the effect of covariates on the cumulative incidence functions (CIFs) for in‑hospital mortality 
and discharge. 426 adult patients [median age 68 (IQR 56 to 77 years)] were admitted with confirmed 
COVID‑19 over a 5‑week period; 292 (69%) were male. By 21 April 2020, 141 (33%) of these patients 
had died, 239 (56%) patients had been discharged and 46 (11%) were still hospitalised. Among these 
46 patients, updated as of 30 May, 2020, 5 (10.9%) had died, 8 (17.4%) were still in ICU, 12 (26.1%) 
were transferred to lower intensity care units and 21 (45.7%) were discharged. Regression on the 
CIFs for in‑hospital mortality showed that older age, male sex, number of comorbidities and hospital 
admission after March 4th were independent risk factors associated with in‑hospital mortality. Older 
age, male sex and number of comorbidities definitively predicted in‑hospital mortality in hospitalised 
patients with COVID‑19.
Since December 2019 SARS COV 2 disease, defined as a pandemic by the World Health Organization (WHO) 
on 11 March 2020, has spread rapidly all over the  world1. Outside China, the first western country to be affected 
was Italy, where the epidemic began on 21 February 2020 and quickly affected thousands of people, practically 
overwhelming the capacity of the National Health System to respond to it in terms of availability of hospital, 
ICU beds and ER spaces to receive and manage  patients2. Although, Policlinico San Matteo is one of the largest 
teaching hospitals (1300 beds) in the region and the Infectious Diseases division managed to more than double 
its total capacity of regular beds from 44 to 94, in the first 2 weeks it experienced difficult in allocating patients, 
because clinical criteria to define the evolution of the disease were, and still are,  missing3.
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To date, most of the studies that have extensively reported the clinical and laboratory characteristics of patients 
infected by COVID-19 have been carried out in  China4. Data on clinical outcomes and treatment of COVID-19 
outside China are lacking and the high heterogeneity in observed case-fatality ratios between and within different 
countries still remains unexplained. Because COVID-19 shows an array of clinical presentations and the lack of 
effective treatment makes it difficult to predict its outcome, the identification of risk factors for clinical outcomes, 
such as death, ICU admission and hospital discharge is crucial in order to improve the organisation of healthcare 
and to identify patients who may benefit the most from the available treatment strategies. Moreover, in such a 
complex epidemiological and clinical scenario, competing risks might help in the assessment of the impact of 
treatment strategies on meaningful clinical endpoints, such as in-hospital death and  discharge5.
The aim of this study was to explore and explain, in a cohort of Lombardy patients with COVID-19 in Pavia, 
Italy, the heterogeneity of clinical outcomes and to identify predictors of in-hospital mortality and discharge by 
competing risks analysis.
Results
From 22 February to 30 March 2020, 426 confirmed cases of COVID-19 were observed, 292 (68.5%) were males 
(Table 1). Median age was 68 years (IQR, 56 to 77 years) and 197 (45.8%) patients were older than 70 years of age. 
269 (63%) patients had at least one comorbidity, with hypertension and diabetes being the most common (140 
(33%) and 63 (15%) patients, respectively). The median score on the Charlson comorbidity index (CCI)6 was 3 
(IQR, 1 to 4) while the median score of Modified Elixhauser score (mEI)7 was 9.2 ± 7.8. The first nasal swab test 
for SARS-COV2 was positive in 365 (86%) patients, while 61 (14%) patients had a negative first nasal swab test 
and positive repeat nasal swab test. Laboratory findings on admission are reported in Table 1. Lymphocytopenia 
was present in 398 (93.3%) patients, while platelet count was lower than 150,000/mmc in 100 (23.5%) patients. 
CRP was increased in 188 (44.0%) patients and LDH was elevated in 369 (87.0%) patients. Chest radiography 
revealed the presence of interstitial pneumonia in 301 (71.0%) patients.
Data on treatments are reported in Table 2. Antibiotic therapy was started in 304 (85%) of patients. Cor-
ticosteroid treatment was administered to 70 (20%) patients and consisted of dexamethasone 20 mg daily in 
13 patients and, starting on 21 March 2020, methylprednisolone 1 mg/kg intravenously daily in 57 patients. 
Hydroxycloroquine, 600 mg twice on day 1, then 400 mg daily for 7 days, was administered to 249 (70.3%) 
patients and was initiated within 72 h following admission. 64 (18.1%) patients did not receive any antiviral 
drug, while 174 (49.1%) patients received antiviral treatment with Lopinavir/ritonavir 400/100 mg twice daily. 
22 (5.2%) patients received Tocilizumab 8 mg/kg from 13 March 2020.
Clinical outcomes. On 21 April 2020, 141 (33.1%) patients had died. The median time from symptoms 
onset to death and from hospitalisation to death was 11 days (IQR 3–19) and 6 days (IQR 3–11), respectively. 
41 (9.6%) patients had been transferred to ICU. The median time from hospitalisation to ICU admission was 
4 days (IQR 2–6). 239 (56%) patients had been discharged and 46 (10.7%) patients were still hospitalised (17 of 
whom were still in ICU). Median time from hospitalisation to discharge was 10 days (IQR 5–18). The outcomes 
of patients who were still hospitalised have been updated as of 30 May, 2020: among these 46 patients, 5 (10.9%) 
had died, 8 (17.4%) were still in ICU, 12 (26.1%) were transferred to lower intensity care units and 21 (45.7%) 
were discharged.
Patients who died were older, had higher CCI and higher mEI score, higher CRP and LDH levels and lower 
lymphocyte count compared to survivor patients (Table 1). Hydroxycloroquine and antibiotics were used more 
frequently in patients who died compared to those who did not. The frequency of complications, such as respira-
tory failure, acute kidney injury, acute cardiac injury and septic shock was significantly higher in patients who 
died as compared to survivors. (Table S1).
Outcomes according to CCI and mEI score are showed in Table S2-S3. Area Under the Curve (AUC) 
for in-hospital mortality prediction was 0.80 (0.75–0.83) for CCI and 0.81 (0.76–0.85) for mEI (p-value for 
comparison = 0.468).
The CIF for in-hospital mortality is showed in Fig. 1. The estimated probability of in-hospital death was 24.4% 
during the first 10 days from hospitalization, 31.0% during the first 20 days and 33.7% at the end of follow-up. 
Univariate analysis for in-hospital mortality is reported in Table S4. Using the Fine and Gray model-to-model 
mortality, older age (70–79 years: HR 4.42, 95% CI 2.59–7.39, p < 0.0001. Over 79 years: HR 7.75, 95% CI 
4.39–13.74, p < 0.0001), male sex (HR 1.85, 95%CI 1.22–2.89, p = 0.003), number of comorbidities higher than 
3 (HR 3.63, p = 0.03), and time of hospital admission (between 4 and 16 March: HR 2.32, 95%CI 1.45–3.71, 
p = 0.001; between 17 and 30 March: HR 1.68, 95%CI 1.03–2.75, p = 0.04) were independently associated with 
higher in-hospital mortality, while time to ICU admission longer than 7 days (HR 0.19, 95%CI 0.05–0.67, 
p = 0.01) were independently associated with lower in-hospital mortality (Table 3). The CIFs for in-hospital 
mortality performed using the parameter estimates of the Fine and Gray model for each of these covariates are 
showed in Figures S1–S4. We also performed a multivariate model including single comorbidities, showing 
similar results (Table S5).
These risk factors were then used to construct a model encompassing all patients grouped into a “best” and 
a “worst” class according to the presence or not of these factors. CIFs for the best class (female patients with less 
than 3 comorbidities, admitted between February, 21 and March, 3) and for the worst class (male patients with 
more than 3 comorbidities, hospitalized between 4 and 16 March) stratified by age group are showed in Fig. 2. 
At the end of follow-up, the probability of in-hospital death in patients younger than 70 years was 1.8% in the 
best class and 18.6% in the worst class. In patients with 70–79 years, the probability of in-hospital death at the 
end of follow-up was 8.3% in the best class and 62.5% in the worst class. In patients older than 80 years, the 
probability of in-hospital death at the end of follow-up was 13.7% in the best class and 80.8% in the worst class.
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The characteristics and outcomes of patients according to the discharge status are reported in Tables S6–S7. 
The CIF for discharge is showed in Fig. 1. The estimated probability of discharge was 30.5% during the first 
10 days from hospitalization, 48.8% during the first 20 days and 61.4% at the end of follow-up Univariate analysis 
is reported in Table S4. Tocilizumab use was significantly associated with a lower probability to be discharged 
at univariate analysis, however it was not included in the multivariate model because only 22 patients received 
Tocilizumab. Using the Fine and Gray model, we observed that lymphocytes count (HR 1.13, 95% CI 1.06–1.19, 
Table 1.  Demographic, clinical and laboratory characteristic of patients on admission. Data are expressed as 
median (interquartile range) or n (%).
Overall (n = 426) Death (n = 141) Survivor (n = 285) p-value
Age (years) 68.0 (56.0–77.0) 77.0 (71.0–83.0) 61.0 (50.0–72.0) <0.0001
< 50 72 (16.9%) 1 (0.7%) 71 (24.9%) <0.0001
50–59 64 (15.0%) 8 (5.7%) 56 (19.6%) 0.0003
60–69 95 (22.3%) 21 (14.9%) 74 (25.9%) 0.014
70–79 125 (29.3%) 66 (46.8%) 59 (20.7%) <0.0001
> 80 70 (16.4%) 45 (31.9%) 25 (8.8%) <0.0001
Male sex 292 (68.5%) 103 (73.0%) 189 (66.3%) 0.194
Comorbidity 269 (63.1%) 116 (82.2%) 153 (53.7%) <0.0001
Hypertension 140 (32.8%) 52 (36.8%) 88 (30.9%) 0.256
Diabetes 63 (14.8%) 28 (19.9%) 35 (12.3%) 0.074
Atrial fibrillation 37 (8.7%) 21 (14.9%) 16 (5.6%) 0.002
Coronary heart disease 36 (8.5%) 25 (17.7%) 11 (3.9%) <0.0001
Obesity 26 (6.1%) 10 (7.1%) 16 (5.6%) 0.636
Chronic kidney disease 25 (5.9%) 16 (11.3%) 9 (3.2%) 0.0007
Chronic heart failure 21 (4.9%) 12 (8.5%) 9 (3.2%) 0.027
Chronic liver disease 21 (4.9%) 11 (7.8%) 10 (3.5%) 0.085
Chronic obstructive lung disease 20 (4.7%) 9 (6.4%) 11 (3.9%) 0.342
History of malignancy 18 (4.2%) 4 (2.8%) 14 (4.9%) 0.467
Active malignancy 16 (3.8%) 8 (5.7%) 8 (2.8%) 0.182
Dementia 12 (2.8%) 9 (6.3%) 3 (1.1%) 0.005
Charlson comorbidity index 3 (1–4) 4 (3–5) 2 (1–3) <0.0001
Modified Elixhauser score 9.2 ± 7.8 15.0 ± 7.9 6.4 ± 5.9 <0.0001
Number of comorbidities <0.0001
0 155 (36.3%) 25 (17.7%) 130 (45.6%)
1 145 (34.0%) 52 (36.9%) 93 (32.6%)
2 73 (17.1%) 34 (24.1%) 39 (13.7%)
More than 3 53 (12.4%) 31 (22.0%) 22 (7.7%)
Median time from symptoms onset to hospitalization 7 (3–10) 6 (3–8) 8 (4–11) 0.037
Time of hospital admission 0.025
From February, 21 to March, 3 137 (32.2%) 36 (25.5%) 101 (35.4%)
From March, 4 to March, 16 165 (38.7%) 67 (40.6%) 98 (34.3%)
From March, 17 to March, 30 124 (29.1%) 38 (27.0%) 86 (30.2%)
Glutamic oxaloacetic transaminase, U/L 41 (28–64) 44 (29–70) 40 (27–57) 0.117
Glutamic pyruvic transaminase, U/L 32 (21–48) 34 (23–53) 31 (21–44) 0.258
C-reactive protein, mg/dL 8.23 (4.14–14.75) 10.40 (5.85–15.00) 7.64 (3.62–14.54) 0.008
C-reactive protein>10 mg/dL 188 (44.1%) 83 (58.9%) 105 (36.8%) <0.0001
Creatinine, mg/dL 0.89 (0.72–1.11) 0.90 (0.75–1.16) 0.87 (0.71–1.09) 0.132
Lactate dehydrogenase, U/L 365 (304–446) 380 (325–455) 365 (294–446) 0.075
Lactate dehydrogenase>245 U/L 369 (86.6%) 129 (91.5%) 240 (84.2%) 0.054
Troponine, ng/L 26 (10–108) 21 (10–55) 37 (11–119) 0.103
White cell blood count, ×  109 per L 6.73 (5.18–9.15) 7.02 (4.95–8.90) 6.65 (5.35–9.3) 0.423
Lymphocyte count, ×  109 per L 0.80 (0.60–1.00) 0.74 (0.60–0.97) 0.80 (0.60–1.01) 0.087
Lymphocyte count<1.5 ×  109 per l 398 (93.3%) 135 (95.7%) 263 (92.3%) 0.250
Neutrophil count, ×  109 per l 5.27 (3.9–7.72) 5.50 (3.61–7.68) 5.2 (3.94–7.75) 0.455
Platelet count, ×  109 per L 204 (152–287) 201 (144–263) 207 (154–296) 0.184
Platelet count < 150 ×  109 per L 100 (23.5%) 39 (27.7%) 61 (21.4%) 0.236
Pneumonia at chest X-ray 301 (70.7%) 130 (92.2%) 171 (60.0%) <0.0001
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p = 0.0001) was independently associated with higher probability to be discharged, while older age (70–79 years: 
HR 0.39, 95%CI 0.27–0.55, p < 0.0001. Over 79 years: HR 0.27, 95% CI 0.16–0.44 p < 0.0001), number of comor-
bidities higher than 3 (HR 0.08, p < 0.0001), and time of hospital admission (between March, 4 and March, 16: 
HR 0.66, 95% CI 0.47–0.92, p = 0.02; between 17 and 30 March: HR 0.68, 95%CI 0.50–0.93, p = 0.02) were inde-
pendently associated with lower probability to be discharged. (Table 3). The CIFs for discharge performed using 










Median time from symptoms onset to death (days) 11 (3–19)
Median time from hospitalization to death (days) 6 (3–11)
Admission to ICU 41 (9.6%)
Median time from symptoms onset to ICU admission (days) 11 (8–13)
Median time from hospitalization to ICU admission (days) 4 (2–6)
Discharge 239 (56.1%)
Median time from symptoms onset to discharge (days) 19 (9–24)
Median time from hospitalization to discharge (days) 10 (5–16)
Respiratory failure 245 (57.5%)
Acute kidney injury 26 (6.1%)
Acute cardiac injury 14 (3.3%)
Septic shock 7 (1.6%)
Thromboembolic events 7 (1.6%)




Scientific Reports |         (2021) 11:1137  | https://doi.org/10.1038/s41598-020-80679-2
www.nature.com/scientificreports/
the parameter estimates of the Fine and Gray model for each of these covariates are showed in Figures S5–S9. 
The CIFs for the best class and for the worst class according to age are showed in Figures S10–S12. At the end of 
follow-up, the probability of discharge in patients younger than 70 years was 99.5% in the best class and 31.5% 
in the worst class. In patients with 70–79 years, the probability of discharge at the end of follow-up was 84.6% 
in the best class and 12.6% in the worst class. In patients older than 80 years, the probability of discharge at the 
end of follow-up was 75.3% in the best class and 9.6% in the worst class.
Discussion
This report, to our knowledge, is the first large retrospective study assessing competing risks in hospitalised 
patients with confirmed COVID-19 in Europe. Older age, male sex, comorbidities and hospital admission sub-
sequent to March, 4 were significantly associated with a higher in-hospital death, by competing risk multivariate 
analysis.
When comparing our cohort with those described in the literature we noted that mortality was higher than 
that observed in other studies conducted both in and outside  China8–10. The median age in our cohort was 
68 years and 77 years in patients who died, which is higher than that observed in other studies. In-hospital 
mortality assessed by competing risks analysis was significantly higher in patients aged between 70 and 79 years 
and in those over 79, compared with patients younger than 70 years. By contrast, the probability of discharge 
was similar between patients of 70–79 years and those older than 79 years. The association between age and in-
hospital mortality could be explained by the lower cardiopulmonary reserve, by the enhanced susceptibility to 
infections and by the inadequate control of anti-inflammatory  mechanisms11.
In our cohort, the median Charlson comorbidity index was 3 and modified Elixhauser Index was 9.2. While 
the prevalence of comorbidities in our cohort was similar to that reported in the  USA10, it was higher than that 
observed in Chinese  cohorts7,8. Our results are in line with those of the Italian National Institute of Health, show-
ing that approximately 61% of deceased Italian patients with COVID-19 had more than 3 comorbidities, while 
only 3.6% of patients who died had no  comorbidity12. It is well known that COVID-19 patients with comorbidi-
ties are at high risk to develop a worst outcome. Several meta-analyses showed that comorbidities (specifically 
hypertension, respiratory system disease, cardiovascular disease, and chronic kidney disease) are associated 
with a higher risk of development of severe COVID-1913–15. Different comorbidity scores have been evaluated 
in COVID-19 patients, such as  CCI10 and mEI  score16. Our analysis showed that these two scores had a similar 
accuracy by AUC for the prediction of in-hospital death.
Male sex was an independent risk factor for in-hospital mortality and a lower probability of discharge. The 
association between gender and worst outcomes in COVID-19 is not fully understood. It has been proposed 
that female sex could be associated with a lower susceptibility to viral infections, with sex hormones playing a 
relevant role in innate and adaptive immune  response17. A different expression of ACE 2 receptor has also been 
suggested as an explanation of the gender-associated mortality in COVID-19  patients18. Conversely, it has been 
suggested that males could be more prone to being affected by COVID-19 due to the higher smoking rate and 
higher prevalence of cardiovascular  comorbidities19. However, our multivariate model suggested that sex was an 
Table 3.  Competing risk analysis by fine and gray model for in-hospital mortality and discharge. *Three 
comorbidities or more versus no comorbidities. Hazard ratio was 2.36 for two comorbidities versus no 
comorbidities and 1.54 for one comorbidity versus no comorbidity. **Three comorbidities or more versus 
no comorbidities. Hazard ratio was 0.19 for two comorbidities versus no comorbidities and 0.44 for one 
comorbidity versus no comorbidity.
Fine and grey model
In-hospital mortality Discharge
Beta Standard error Hazard ratio p value Beta Standard error Hazard ratio p value
Age 70–79 years 1.49 0.27 4.42 <0.0001 − 0.95 0.19 0.39 <0.0001
Age > 80 years 2.05 0.29 7.75 <0.0001 − 1.31 0.25 0.27 <0.0001
Male sex 0.64 0.22 1.89 0.003 − 0.66 0.14 0.52 <0.0001
Number of comorbidities 0.52 0.25 3.63* 0.038 − 0.62 0.21 0.08** 0.003
Admission between March, 
4 and March, 16 0.84 0.23 2.32 0.001 − 0.42 0.17 0.66 0.015
Admission between March, 
17 and March, 30 0.52 0.25 1.68 0.048 − 0.39 0.16 0.68 0.017
Lymphocyte count, ×  109 
per L − 0.22 0.22 0.80 0.316 0.12 0.03 1.13 0.0001
Hydroxychloroquine − 0.13 0.27 0.88 0.639 − 0.27 0.16 0.76 0.760
No ICU admission 0.34 0.45 1.41 0.449 Baseline
Time to ICU admission 
lower than 3 days Baseline − 0.61 0.32 0.54 0.056
Time to ICU admission 
between 4 and 6 days − 0.61 0.63 0.54 0.330 − 0.02 0.27 0.98 0.955
Time to ICU admission > 
7 days − 1.67 0.65 0.19 0.010 − 0.01 0.01 0.99 0.996
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Figure 2.  Cumulative incidence functions for in-hospital mortality performed using the parameter estimates 
of the Fine and Gray model and considering the best patient profile (female sex, number of comorbidities lower 
than 3 admitted between 21 February to 3 March 2020) and the worst patient profile (male sex, number of 
comorbidities higher than 3, admitted between 4 and 16 March 2020) according to age groups. (A) Age lower 
than 70 years. (B) Age between 70 and 79 years. (C) Age higher than 79 years.
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independent predictor of mortality, and discharge regardless of comorbidities and evidence supporting smok-
ing as a predisposing factor in men with COVID-19 are lacking. Unfortunately, we were unable to evaluate the 
association between smoking and clinical outcomes in COVID-19.
Patients who were admitted during the first weeks of the emergency had a significantly lower in-hospital 
mortality and a higher likelihood of discharge compared to those who were admitted during subsequent weeks, 
with the worst outcomes observed from 4 to 16 March 2020. One factor that many reports have addressed is the 
sequence of phases into which the disease has been divided, each corresponding to a different pattern of viral 
and immunological factors. Patient presentation in late phase may also have occurred, leading to the admission 
of an exceptionally large number of patients who needed hospitalisation in a short time span, resulting in a 
critical overload in the Policlinico San Matteo, in both triage and the management of the disease. These findings 
may be explained by also taking into consideration that during the first week many admissions were made for 
epidemiological reasons, leading to the hospitalisation of patients with few symptoms or mild disease.
Although ICU admission after 7 days from hospitalisation was independently and significantly associated 
with a lower risk of in-hospital mortality, the rapidity with which patients entered the ICU often concurrently 
with initiating other treatments makes the benefit of this treatment difficult to assess. Moreover, results from 
observational studies of drug effects should be interpreted with caution as they may be biased by survivor treat-
ment selection bias, including time-related  biases20,21.
In the literature, the use of composite endpoints (i.e. death or ICU admission) and, on the other hand, the 
implementation of traditional survival and Cox models are not appropriate in a disaster medicine setting such as 
that of COVID-19. The first assumption considers ICU and death to be equal, which is not true, while the tradi-
tional Cox model neglects to model discharge as an alternative endpoint. Competing risks analysis may provide 
further insights into the effect of interventions on the separate endpoint  components22. We overcame this issue 
by performing a competing risks analysis taking into account two events (in-hospital death and discharge) and 
including ICU admission as a time-dependent  covariate23. We suggest the use of a standardised methodology 
to assess treatment effects in observational studies in the complex clinical scenario of COVID-19. It should be 
underlined that COVID-19 case fatality ratio requires a dynamic  assessment24 and that it decreased dramati-
cally in Italy during the months that followed our study. This is could be to the improvements of the supportive 
treatments, as well as the general organization and bed occupancy. The competing risks model adopted is able to 
recognize effective and non effective predictors, as, for instance, our model excluded treatments since the very 
beginning. Nevertheless, we are aware that unknown risk factors are still incumbent in all the statistical analyses 
conducted till now, so frailty survival models can be applied in order to capture eventual and unknown source of 
variability. Summarising all the available evidence from randomised controlled trials and real-world comparative 
effectiveness studies, we are convinced that effective treatments for COVID-19 are still lacking and that therapies, 
such as specific antiviral drugs and immunomodulatory agents, remain an unmet and urgent medical need.
The main limitation of our study is the retrospective design. Retrospective studies have many problems that 
reduce their internal and external validity. When assessing retrospective cohort studies, the most important bias 
is the likelihood of the inappropriate selection of patients, which can lead to incorrect results and spurious asso-
ciations. However, we included only consecutive patients with confirmed COVID-19, therefore we believe that 
selection bias was not relevant. Moreover, some potential confounders associated with the severity of COVID-19 
(i.e. P/F ratio or circulating cytokine levels) and not available for this modelling could affect our results. Thus, 
we performed multivariate competing risks analysis to overcome this issue. Other limitations are the generalis-
ability of our results to different populations and settings, particularly regarding the demographic structure of 
our country, including European elderly patients with a high prevalence of comorbidities. Finally, mortality 
was limited to in-hospital death, and discharged patients were assumed to still be alive during the study period.
In conclusion, our findings indicate that in a Lombardy cohort of elderly hospitalized patients, for the most 
part male with a high prevalence of comorbidities, COVID-19 is characterised by high in-hospital mortality. 
Older age, male sex, comorbidities and time of admission were found to be significant risk factors for in-hospital 
mortality and associated with a lower probability of being discharged.
Methods
Study setting. The SMatteo COvid19 Registry (SMACORE) is a cohort of patients with a confirmed diag-
nosis of COVID-19 disease referred to the IRCCS Policlinico San Matteo Hospital of Pavia, Italy from February 
2020. The SMACORE database includes demographic, clinical laboratory tests, treatment, and outcome data. 
Ethics approval for observational research using SMACORE data was obtained from the local ethics committee.
This is a single centre, retrospective, observational cohort study and all patients of SMACORE cohort con-
secutively admitted to the Infectious Diseases Unit between 22 February and 30 March 2020, with a diagnosis of 
COVID-19 were enrolled. ICD-9 CM codes were reviewed, and clinical data were further extracted and reviewed 
by consulting the medical charts. Patients were followed until 21 April 21 2020. Laboratory confirmation of the 
SARS COV-2 infection was defined as positive Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) from clinical nasal swab.
Statement. All methods were carried out in accordance with relevant guidelines and regulations and Ethics 
approval for observational research using SMACORE data was obtained from the local ethics committee and the 
informed consent has been obtained as by internal procedures.
Data source. Demographic, clinical, laboratory, treatment, and outcome data were extracted from medical 
records using a standardised data collection form. The Charlson comorbidity index (CCI) and the modified 
Elixhauser index (mEi) were used to assess  comorbidity6,7. CCI includes 16 comorbidities, predicting 10-year 
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survival in patients with multiple comorbidities and was used as a measure of the total comorbidity burden. The 
mEi includes 11 comorbidities and it has been recently assessed in patients with COVID-1916. Imaging examina-
tions were based on chest X-ray results. Although the benefits of a chest CT scan in achieving an early diagnosis 
of COVID-19 and in the follow-up of pneumonia evolution are well  known25, we did not have the opportunity 
to include them in our clinical workout.
Laboratory tests. Respiratory samples from the upper respiratory tract were prospectively collected and 
analysed at the Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, as part of the 
Regional SARS-CoV-2 surveillance and diagnosis plan in the Lombardy region. Total nucleic acids (DNA/RNA) 
were extracted from 200 ul of UTM using the QIAsymphon instrument with QIAsymphony DSP Virus/Patho-
gen Midi Kit (Complex 400 protocol) according to the manufacturer’s instructions (QIAGEN, Qiagen, Hilden, 
Germany). Specific RT-PCR targeting RNA-dependent RNA polymerase and E genes were used to detect the 
presence of SARS-CoV-2 in respiratory samples according to the WHO guidelines and published  protocols26,27.
Routine blood examinations included complete blood count, serum creatinine, glutamic oxaloacetic transami-
nase (GOT) and glutamic pyruvic transaminase (GPT), lactate dehydrogenase (LDH), C-reactive protein (CRP) 
and troponin. Lymphocitopenia was defined as lymphocyte count < 1.5 × 109/L. CRP was considered elevated 
above 10 mg/dL. LDH levels were considered elevated above 245 U/L. Blood cultures were performed in each 
patient and arterial-blood gas analysis (ABG) was performed when clinical signs of oxygen impairment were 
detected (e.g. tachypnoea and hypoxia).
Treatment data. Treatment data included use of lopinavir/ritonavir, hydroxychloroquine, corticoster-
oids, tocilizumab and antibiotic drugs. Lopinavir/ritonavir 400/100 mg was administered orally twice daily for 
14 days. Hydroxychloroquine (HCQ) 600 mg twice on day 1, then 400 mg daily for 7 days. Corticosteroid treat-
ment consisted of dexamethasone 20 mg daily for 5 days in patients admitted from 22 February to 20 March and 
methylprednisolone 1 mg/kg intravenously daily for 5 days from 21 March to the end of follow-up. Tocilizumab 
8 mg/kg was given intravenously in 1 or 2 doses from 13 March to the end of follow-up. A second dose was given 
8–12 h after the first dose in patients with inadequate response. Antibiotic therapy consisted of a combination 
of piperacillin/tazobactam and doxycycline. Low (cannula and simple masks) and high (Venturi and reservoir 
masks, Nasal High Flow (NHF), helmet continuous positive airway pressure (CPAP)) flow oxygen support was 
provided when hypoxia was detected. Time to ICU admission was defined as the time from hospitalisation to 
ICU admission.
Outcomes. The primary disease event was in-hospital mortality. Discharge was analysed as a competing 
event by competing risks analysis.
The criteria for discharge were absence of fever, clinical remission of respiratory symptoms, oxygen satura-
tion greater than 94% and two nasal swab samples negative for SARS-CoV-2 RNA obtained at least 24 h apart.
Septic shock was defined according to the 2016 Third International Consensus Definition for Sepsis and Septic 
 Shock28. Acute kidney injury was defined according to the KDIGO clinical practice  guidelines29 and acute cardiac 
injury was diagnosed if serum levels of cardiac biomarkers (troponin) was above the 99th percentile upper refer-
ence limit, or if new abnormalities were shown in electrocardiography and  echocardiography30.
Statistical analysis. Data for continuous variables are presented as mean and standard deviation or median 
and interquartile ranges (IQR), and data for categorical variables are presented as frequency and percentage. 
Differences between continuous data were analysed by Student t test or by Mann–Whitney U test. Differences 
between categorical variables were analysed by χ2 test.
In-hospital mortality and discharge were evaluated by competing risks analysis, using cumulative incidence 
function (CIF)5. The proportional sub-distribution hazard model by Fine and Gray was fitted in order to estimate 
the effect of covariates on CIFs in-hospital death and discharge, including ICU admission as a time-dependent 
 covariate31. Covariates used for multivariate analyses were chosen based on their significance in the univariate 
analysis (p < 0.10). Variables in the final model with a p-value < 0.05 were considered statistically significant. The 
results are expressed as adjusted hazard ratios (HR) and their 95% confidence intervals (CI). Discrimination 
of CCI and mEi for the prediction of in-hospital mortality was assessed by the area under the receiver operat-
ing characteristic curve (AUC). DeLong method was used to test whether the differences between AUCs were 
statistically  significant32. Models used a complete-case analysis approach. Statistical analyses were completed 
in SAS version 9.4.
Ethics approval. The study was approved by Fondazione IRCCS Policlinico San Matteo institutional review 
board for observational research using SMACORE data.
Data availability
The authors agree to share relevant, anonymized data generated as part of the SMAtteo COvid19 REgistry 
(SMACORE) upon reasonable request.
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